CRISPR-Edited immune cells battle tough cancers in new trial
Disease control
Completed
This study tested a new type of cell therapy called CTX131 for adults with advanced solid tumors that have returned or stopped responding to standard treatments. CTX131 uses a patient's own immune cells that are genetically modified in a lab to better target and fight cancer cell…
Phase: PHASE1, PHASE2 • Sponsor: CRISPR Therapeutics AG • Aim: Disease control
Last updated Mar 30, 2026 14:29 UTC